MA38462A1 - Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes - Google Patents
Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomesInfo
- Publication number
- MA38462A1 MA38462A1 MA38462A MA38462A MA38462A1 MA 38462 A1 MA38462 A1 MA 38462A1 MA 38462 A MA38462 A MA 38462A MA 38462 A MA38462 A MA 38462A MA 38462 A1 MA38462 A1 MA 38462A1
- Authority
- MA
- Morocco
- Prior art keywords
- lymphoma
- compound
- hodgkin
- bcr
- pharmaceutical composition
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 title 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000004480 active ingredient Substances 0.000 abstract 5
- 230000004913 activation Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 101150090105 Ezh2 gene Proteins 0.000 abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 201000003444 follicular lymphoma Diseases 0.000 abstract 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 abstract 2
- 208000021937 marginal zone lymphoma Diseases 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 230000000306 recurrent effect Effects 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- -1 2,3-dihydroimidazo [1,2-c] quinazoline compound Chemical class 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 abstract 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002751 lymph Anatomy 0.000 abstract 1
- 208000025036 lymphosarcoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur l'utilisation d'un composé de 2,3-dihydroimidazo[1,2-c]quinazoline, ou d'une composition pharmaceutique contenant celui-ci, en tant que seul principe actif, ou d'une association de a) ledit composé ou ladite composition pharmaceutique contenant ledit composé et b) un ou plusieurs autres principes actifs, pour la préparation d'un médicament pour le traitement ou la prophylaxie d'un lymphome non hodgkinien (lnh), en particulier un lymphome non hodgkinien (lnh) de 1ère ligne, de 2nde ligne, récidivant, réfractaire, indolent ou agressif, en particulier un lymphome folliculaire (lf), une leucémie lymphocytaire chronique (llc), un lymphome de la zone marginale (lzm), un lymphome diffus à grandes cellules b (ldgcb), un lymphome à cellules du manteau (lcm), un lymphome transformé (lt) ou un lymphome t périphérique (ltp); sur des associations de a) ledit composé et b) un ou plusieurs autres principes actifs; sur une composition pharmaceutique comprenant ledit composé en tant que seul principe actif pour le traitement d'un lymphome non hodgkinien (lnh), en particulier un lymphome non hodgkinien (lnh) de 1ère ligne, de 2nde ligne, récidivant, réfractaire, indolent ou agressif, en particulier un lymphome folliculaire (lf), une leucémie lymphocytaire chronique (llc), un lymphome de la zone marginale (lzm), un lymphome diffus à grandes cellules b (ldgcb), un lymphome à cellules du manteau (lcm), un lymphome transformé (lt) ou un lymphome t périphérique (ltp); sur une composition pharmaceutique comprenant une association de a) ledit composé et b) un ou plusieurs autres principes actifs; sur l'utilisation de biomarqueurs impliqués dans la modification de l'expression d'isoformes de pi3k, de btk et d'ikk, l'activation du bcr, l'activation en aval du bcr de la voie nfkb, de c-myc, d'ezh2, pour la prédiction de la sensibilité et/ou la résistance d'un patient cancéreux audit composé et pour la production d'une association synergétique rationnelle selon la présente invention pour augmenter la sensibilité et/ou pour surmonter la résistance; et sur un procédé de détermination du taux d'un ou plusieurs composants d'expression d'isoformes de pi3k, de btk et d'ikk, d'activation du bcr, d'activation en aval du bcr de la voie nfkb, de c-myc, d'ezh2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162710 | 2013-04-08 | ||
| PCT/EP2014/056768 WO2014166820A1 (fr) | 2013-04-08 | 2014-04-04 | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38462A1 true MA38462A1 (fr) | 2017-10-31 |
Family
ID=48045340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38462A MA38462A1 (fr) | 2013-04-08 | 2014-04-04 | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA38462A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839659A (zh) * | 2018-08-14 | 2021-05-25 | 梅制药公司 | 复发性滤泡性淋巴瘤的治疗 |
-
2014
- 2014-04-04 MA MA38462A patent/MA38462A1/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839659A (zh) * | 2018-08-14 | 2021-05-25 | 梅制药公司 | 复发性滤泡性淋巴瘤的治疗 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792650A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| Vaidyanathan et al. | ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells | |
| Shi et al. | Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation | |
| Grisold et al. | Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention | |
| Kolev et al. | Inhibition of FAK kinase activity preferentially targets cancer stem cells | |
| Yang et al. | RARα2 expression confers myeloma stem cell features | |
| Daniele et al. | Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells | |
| Rosich et al. | Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma | |
| Whang et al. | LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells | |
| Paulus et al. | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment | |
| Chen et al. | Dual cyclin‐dependent kinase 4/6 inhibition by PD‐0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells | |
| Zhang et al. | Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells | |
| Pazhouhi et al. | Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG) | |
| Grahovac et al. | Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics | |
| Ko et al. | Resveratrol Enhances Etoposide‐Induced Cytotoxicity through Down‐Regulating ERK 1/2 and AKT‐Mediated X‐ray Repair Cross‐Complement Group 1 (XRCC 1) Protein Expression in Human Non‐Small‐Cell Lung Cancer Cells | |
| Follin-Arbelet et al. | The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM | |
| Li et al. | Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality | |
| Chae et al. | Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways | |
| Visco et al. | The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines | |
| Ko et al. | HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells | |
| Wu et al. | Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner | |
| Martín-Sánchez et al. | PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases | |
| Rogers-Broadway et al. | Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro | |
| Lin et al. | Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1 | |
| Lim et al. | Co-treatment with celecoxib or NS398 strongly sensitizes resistant cancer cells to antimitotic drugs independent of P-gp inhibition |